CO-005 / Caedo Oncology - LARVOL DELTA

Development of a novel bifunctional anti-CD47 fusion protein with improved efficacy and a favorable safety profile. (PubMed, Mol Cancer Ther) - "The ability of CO-005 to trigger strong PCCD while preserving conventional immune responses provides a novel and promising approach for CD47-targeted cancer therapy. Its favorable safety profile, observed in both in vitro and ex vivo studies, positions CO-005 as a promising candidate with potential therapeutic advantages over existing anti-CD47 treatments."

Journal • Hematological Disorders • Hematological Malignancies • Lymphoma • Oncology • SIRPA